glp 1 community Holding space* for community, connection, commiseration, accountability and healthy habit formation. GLP-1s work BETTER TOGETHER. Gather with us at peoplehood.com 🤎 GLP-1 Agonists - What is

The Mullen & Mullen family is here to address your concerns and make the path to recovery smooth

This might involve: Increasing metformin dosage if not already at maximum tolerated dose Adding or optimising sulfonylureas such as gliclazide, though these carry hypoglycaemia risk Introducing DPP-4 inhibitors like sitagliptin or linagliptin, which are generally well-tolerated Adding pioglitazone in carefully selected patients, considering both potential benefits and significant risks (fluid retention, weight gain, heart failure risk, fracture risk, and possible bladder cancer risk) Insulin therapy may be necessary if other options are insufficient to achieve target HbA1c levels

The plotter shows concentration

LAMP Makes Liraglutide Interesting, Not Settled The LAMP liraglutide trial enrolled 636 patients and reported lower recurrence, HR 0.56, 95% CI 0.34-0.91, P 0.02, plus better 90-day outcomes, OR 1.95, 95% CI 1.28-3.00, P 0.002

As type 2 diabetes becomes a more common condition among women of reproductive age, and with the recent approval of GLP-1 receptor agonists such as semaglutide to treat obesity, the number of exposed pregnancies is likely to increase